AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THALES Study for Patients with Minor Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

 AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THALES Study for Patients with Minor Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THALES Study for Patients with Minor Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Shots:

  • The P-III THALES study involves assessing of Brilinta (90mg, bid) + aspirin vs aspirin as monothx. in 11,000+ patients with minor acute ischemic stroke or high-risk TIA in the 24hrs. prior to treatment initiation
  • The P-III THALES study resulted in a reduction in risk of stroke and death after an acute ischemic stroke or TIA, improved outcomes, the reduction in risk of devastating events, safety is consistent with the known profile along with an increment in bleeding rate
  • Brilinta is a reversible, direct-acting P2Y12 receptor antagonist acts by inhibiting platelet activation, co-administered with aspirin to prevent atherothrombotic events in adult patients with ACS or MI

Click here ­to­ read full press release/ article | Ref: AstraZeneca  | Image: AstraZeneca

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post